Device Trial Radar · NCT02686125
Vercise™ DBS Dystonia Prospective Study
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Mar 7, 2016
Primary completion
Dec 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Feb 19, 2016
Design
- Study type
- Observational
- Who can join
- All sexes, from 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compile characteristics of real-world outcomes of Boston Scientific Corporation's commercially approved VerciseTM Deep Brain Stimulation (DBS) Systems for the treatment of dystonia.
Conditions
- Dystonia
Interventions
Deep Brain Stimulation (DBS)Device
Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their dystonia symptoms will be offered participation in this registry.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with reduction in dystonia symptoms as assessed by BFMDRS scoreTime frame: up to 3 years
- Proportion of cervical dystonia subjects with reduction in symptoms as assessed by TWSTRS scoreTime frame: up to 3 years
Locations
36 sites in 12 countries. Site status is shown where the registry gives one.
AZ Sint-Lucas
Ghent, Belgium · Terminated
UZ Gasthuisberg
Leuven, Belgium · Recruiting
Queen Elizabeth II Health Sciences Center
Halifax, Canada · Recruiting
33 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.